Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study.
Journal: Journal of comparative effectiveness research
Published: March 12, 2026
FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 07, 2025
FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 20, 2024
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.
Journal: Cancer discovery
Published: December 12, 2023
Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 18, 2022
The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990-2018.
Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Published: November 07, 2022
Mobilizing the clinical trial ecosystem to drive adoption of master protocols.
Journal: Clinical trials (London, England)
Published: September 10, 2022
The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.
Journal: The Lancet. Oncology
Published: March 18, 2022
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Journal: Pediatric blood & cancer
Published: October 27, 2021
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 08, 2021
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Journal: The oncologist
Published: April 20, 2021
FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patients.
Journal: Pediatric blood & cancer
Published: January 26, 2020
Last Updated: 09/26/2026